research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
Search
for
Sort by
Research
30 / 1000+ results 
research A Comparative study of Regulations of Cell and Gene therapy in US, EU and India
The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.
research Artificial Hair: By the Dawn to Automatic Biofibre® Hair Implant
Biofibre® hair implants are safe and effective for alopecia when proper procedures are followed, with high patient satisfaction.
research Exosomes in precision dermatology: From biomarkers to targeted therapeutics in personalized care
Exosomes show promise in dermatology but need more research and FDA approval for clinical use.
research Changes in European Legislation Make it Timely to Introduce a Transparent Market Surveillance System for Cosmetics
Europe needs a clear system to watch over cosmetics for safety and to make sure product claims are true.
research Cushing's syndrome in the elderly: data from the European Registry on Cushing's syndrome
Older patients with Cushing's syndrome often have different symptoms and treatment outcomes compared to younger patients.
research FDA declines approval of testosterone drug for third time
The FDA rejected a testosterone drug again due to safety concerns.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology
People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.
research Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence
Hormone therapy for trans individuals is effective and generally safe in the short term.
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research Purpose-limited pharmaceutical product claims under the revised European Patent Convention: A camouflaged attack on generic substitution?
The revised European Patent Convention may limit generic drug use, affecting healthcare professionals' treatment choices.
research Efficacy of Cosmerna ARI in Improving Androgenetic Alopecia in Europeans: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial over 6 months
Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
research Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Lower Urinary Tract Symptoms: What’s New in Medical Treatment?
New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
research Prescription Appropriateness of Cyproterone Acetate/Ethinylestradiol in Primary Care: A Population-Based Study in Italy
The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.
research Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: e-Posters
Rare ULBP3 gene changes may raise the risk of Alopecia areata, a certain FAS gene deletion could cause a dysfunctional protein in an immune disorder, and having one copy of a specific genetic deletion is okay, but two copies cause sickle cell disease.
research NANOCARRIER-BASED DELIVERY OF MINOXIDIL: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS IN ALOPECIA THERAPY
Nanocarriers could improve minoxidil delivery for better hair loss treatment.
research NANOCARRIER-BASED DELIVERY OF MINOXIDIL: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS IN ALOPECIA THERAPY
Nanocarrier systems could improve hair loss treatments by delivering drugs more effectively.
research Patient prioritisation of impact items to develop the patient‐reported impact of dermatological diseases (PRIDD ) measure: European Delphi data
Patients with skin diseases rated psychological effects as most impactful, needing a treatment approach that addresses both mind and body.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Common Variants in the Trichohyalin Gene Are Associated with Straight Hair in Europeans
Common variants in the Trichohyalin gene are linked to straight hair in Europeans.
research Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry—The European and North America Regulation Challenges
Nanocarriers can enhance cosmetics but face regulatory and safety challenges.
research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
Disease-specific tools better assess alopecia areata's impact on quality of life.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research Alopecia Areata: An Updated Review for 2023
Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
research International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.